ZEJULA (niraparib) Extends PARP Inhibitor
Therapy to More Women1
EXPLORE WHAT ZEJULA CAN OFFER PATIENTS WITH OVARIAN CANCER
IN THE FOLLOWING INDICATIONS1:
FDA-approved indications for ZEJULA1


In QUADRA, HRD-positive status (HRD+) was determined using the Myriad myChoice® CDx as either tBRCAm and/or GIS+ (genomic instability score [GIS] ≥42).1
Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.
ZEJULA is the only once-daily oral
PARP inhibitor monotherapy for ovarian cancer1-3